Abstract:
HARES is a supportive (high G\') HA filler with a low degree of water affinity (gel swelling) and modification (<1% BDDE) that has a well-established safety and efficacy profile in the literature, especially for infraorbital hollow (IOH) rejuvenation. To further support the safety of this product, a long-term review of delayed-onset adverse events of interest (DAEIs) related to HARES was conducted using reports from a global post-marketing safety surveillance database over the past 23 years. This review demonstrated low reporting frequencies of delayed-onset nodules and inflammatory events, establishing a long-term safety profile for HARES that supports its continued use in clinical practice, especially for IOH rejuvenation.
摘要:
HARES是一种支持性(高G\')HA填充剂,具有低程度的水亲和力(凝胶溶胀)和改性(<1%BDDE),在文献中具有良好的安全性和有效性。特别是对于眶下中空(IOH)复兴。为了进一步支持本产品的安全性,本研究利用过去23年全球上市后安全监测数据库的报告,对与HARES相关的迟发性不良事件(DAEI)进行了长期审查.这篇综述显示延迟发作结节和炎症事件的低报告频率。建立HARES的长期安全性,支持其在临床实践中的持续使用,特别是IOH复兴。